Healthcare - Biotechnology - NASDAQ - US
$ 17.85
-6.25 %
$ 668 M
Market Cap
12.4
P/E
CASH FLOW STATEMENT
140 M
OPERATING CASH FLOW
-138 M
INVESTING CASH FLOW
21 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Entrada Therapeutics, Inc.
| Net Income | -6.68 M |
| Depreciation & Amortization | 2.84 M |
| Capital Expenditures | -5.61 M |
| Stock-Based Compensation | 13.1 M |
| Change in Working Capital | 136 M |
| Others | 133 M |
| Free Cash Flow | 134 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (6.7) | (94.6) | (51.2) | (26.5) | (5.1) |
| Depreciation & Amortization | 2.8 | 1.9 | 1.1 | 0.3 | 0.1 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 13.1 | 9.9 | 2.5 | 0.3 | 0.3 |
| Other Operating Activities | (5.8) | 0.2 | 74 K | 20 K | (6.3) |
| Change in Working Capital | 136.3 | (11.1) | (3.4) | 0.3 | 0.2 |
| Cash From Operations | 139.8 | (93.8) | (50.9) | (25.6) | (10.8) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (5.6) | (2.9) | (4.6) | (2.3) | (0.6) |
| Other Items | (132.8) | (145.8) | 0 | 7 K | 0 |
| Cash From Investing Activities | (138.4) | (148.7) | (4.6) | (2.3) | (0.6) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0.3 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.6 | 0.5 | 116.8 | 50.1 | 38 K |
| Cash From Financing Activities | 21.0 | 0.5 | 307.5 | 50.1 | 38 K |
| CHANGE IN CASH | |||||
| Net Change In Cash | 22.4 | (242.0) | 252.0 | 22.2 | (11.4) |
| FREE CASH FLOW | |||||
| Free Cash Flow | 134.2 | (96.7) | (55.4) | (27.9) | (11.4) |